We are 3-Hydroxy-N-Methyl-3-Phenyl-Propylamine CAS:42142-52-9 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
Chemical Name: 3-Hydroxy-N-Methyl-3-Phenyl-Propylamine
Molecular Weight: 165.23200
Physical and Chemical Properties:
Density: 1.017 g/cm3
Boiling point: 170 °C / 31mmHg
Melting point: 64 °C
Flash point: 114.8±16.0 °C
Refractive index: 1.531
Appearance: White crystalline powder
Residue on ignition:≤0.1%
25kg cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Fluoxetine hydrochloride CAS:59333-67-4
Intermediates of Atomoxetine hydrochloride CAS:82248-59-7
Related News: Once they have decided how to make the compound, our staff in the production department manufacture a high quantity of APIs using the large reactors in our plant.Dimetoxi (metil) (3,3,3-trifluoropropil) silano CAS:358-67-8 The upstream of pharmaceutical intermediates is the basic chemical raw material industry. Basic chemical raw materials are bulk commodities and prices fluctuate greatly, which directly affects the production costs of enterprises.149490-60-8 Active pharmaceutical ingredients directly impact disease.Diallylamine CAS:124-02-7 As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company’s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations.High-barrier generic drugs: Usually for the production of drugs whose patents have just expired or are about to expire, the market is only competed by original research and a few generic drug companies.